RxDoctor Payments Data

Patrick Young, MD

Psychiatry · Dallas, TXNPI 1508082652

Payments from drug & device makers

$18,567in general payments, 2019–2025

Across 90 payments — averaging $206.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Otsuka America Pharmaceutical, Inc.$444
  • Johnson & Johnson$282
  • Lundbeck LLC$207
  • Neurocrine Biosciences, Inc.$121
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$97
  • plus $251 from 6 others

What the payments were for

  • Speaking & faculty fees$16,35488%
  • Travel & lodging$6003%
  • Food & beverage$1,5148%
  • Education$991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,567 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$30,664
Medicare patients
44
Services billed
822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate114$373,691
IngrezzaValbenazine Tosylate38$317,373
AustedoDeutetrabenazine13$171,402
VraylarCariprazine Hcl75$106,704
RexultiBrexpiprazole42$68,105
Abilify MaintenaAripiprazole17$48,487
Lurasidone Hcl28$13,282
Clozapine96$6,365
Divalproex Sodium ErDivalproex Sodium74$5,574
Olanzapine126$4,225
Chlorpromazine Hcl11$3,933
Aripiprazole59$3,383
Vilazodone Hcl26$2,655
Quetiapine Fumarate136$2,631
Bupropion XlBupropion Hcl160$2,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$282$373,691114 claims
Neurocrine Biosciences, Inc.Ingrezza$121$317,37338 claims
Teva Pharmaceuticals USA, Inc.Austedo$78$171,40213 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$444$116,59259 claims
AbbVieVraylar$17,165$106,70475 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →